Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133056 | 0.81 | SCN8A (0.43) | GPR84ARADRA2ASCN8ASCN10A | |
| SCHEMBL8134030 | 0.74 | EPHX1 (0.64) | ABL1EPHX1 | |
| SCHEMBL3662823 | 0.72 | ABL1 (0.54) | ABL1ADRA2AEPHX1 | |
| SCHEMBL4893047 | 0.72 | ABL1 (0.42) | GPR84ABL1ADRA2A | |
| SCHEMBL3400985 | 0.71 | ADRA2A (0.53) | GPR84ABL1ADRA2AEPHX1 | |
| SCHEMBL1241959 | 0.71 | ABL1 (0.56) | ABL1ADRA2ASCN8A | |
| SCHEMBL24517467 | 0.70 | — | — | |
| SCHEMBL28317581 | 0.70 | ADRA2A (0.47) | GPR84ABL1ARADRA2A | |
| SCHEMBL606375 | 0.70 | ELANE (0.46) | GPR84ELANE | |
| SCHEMBL11498100 | 0.69 | ABL1 (0.59) | ABL1ADRA2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | GPR84 3400/4885ABL1 4124/4885AR 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.